Research Topics
Genomes and GenesSpecies | Maria D CappelliniSummaryAffiliation: University of Milan Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Myocardial involvement during the early course of type 2 diabetes mellitus: usefulness of myocardial performance indexPaolo Pattoneri
Department of Internal Medicine, Nephrology and Health Sciences, University of Parma, Italy
Cardiovasc Ultrasound 6:27. 2008..These abnormalities can provide a feasible approach to detect a pre-clinical diabetic cardiomyopathy and could be useful for an indirect assessment of the metabolic control...
Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-upM Domenica Cappellini
Universita di Milano, Ca Granda Foundation Istituto di Ricovero e Cura a Carattere Scirntifico IRCCS, Milan, Italy
Blood 118:884-93. 2011..This trial was registered at www.clinicaltrials.gov as #NCT00171210...
Current status in iron chelation in hemoglobinopathiesMaria D Cappellini
Department of Internal Medicine, Policlinico, Mangiagalli Regina Elena Foundation IRCCS, University of Milan, Via F Sforza 35, 20122 Milano, Italy
Curr Mol Med 8:663-74. 2008..The efficacy and safety profile have been evaluated in more than 1000 patients in clinical trials allowing FDA registration. Patient satisfaction with Deferasirox was superior than with DFO therapy...
Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overloadM D Cappellini
University of Milan, Department of Internal Medicine, Policlinico Foundation IRCCS, Milan, Italy
Expert Opin Pharmacother 9:2391-402. 2008..While deferoxamine, the current standard of care, is an effective iron chelator, it requires subcutaneous infusion for 8-12 h/day, 5-7 days/week. This regimen is problematic and impacts significantly on patients' daily life...
Coagulation and splenectomy: an overviewM D Cappellini
Department of Internal Medicine, Hereditary Anemia Center, Fondazione Policlinico, Mangiagalli, Regina Elena, IRCCS, University of Milan, Milan, Italy
Ann N Y Acad Sci 1054:317-24. 2005....
Long-term efficacy and safety of deferasiroxMaria Domenica Cappellini
Foundation Ospedale Maggiore Policlinico IRCCS, University of Milan, Milan, Italy
Blood Rev 22:S35-41. 2008..It is recommended that patients treated with deferasirox are monitored regularly for iron status and adverse events, to ensure that an effective and tolerable iron chelation regimen is established for each individual patient...
Glucose-6-phosphate dehydrogenase deficiencyM D Cappellini
Department of Internal Medicine, University of Milan, Policlinico, Mangiagalli, Regina Elena Foundation IRCCS, Via F Sforza 35, Milan, Italy
Lancet 371:64-74. 2008..The most effective management of G6PD deficiency is to prevent haemolysis by avoiding oxidative stress. Screening programmes for the disorder are undertaken, depending on the prevalence of G6PD deficiency in a particular community...
Iron-chelating therapy with the new oral agent ICL670 (Exjade)M D Cappellini
Centro Anemie Congenite, Ospedale Maggiore Policlinico IRCCS, Via F Sforza 35, 20122 Milano, Italy
Best Pract Res Clin Haematol 18:289-98. 2005..These encouraging results have provided the rationale for the ongoing phase III programme, and offer physicians and patients the promise of an oral, once-daily, iron-chelating agent for the prevention and management of iron overload...
Overcoming the challenge of patient compliance with iron chelation therapyM D Cappellini
Centro Anemie Cogenite, Ospedale Maggiore Policlinico, IRCCS, University of Milan, Milano, Italy
Semin Hematol 42:S19-21. 2005
Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemiaMaria Domenica Cappellini
Fondazione Policlinico IRCCS, Universitd di Milano, Milan, Italy
Clin Ther 29:909-17. 2007..Deferasirox is an orally administered iron chelator that has been approved for use in the United States, Switzerland, and other countries...
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemiaMaria Domenica Cappellini
Fondazione Ospedale Maggiore Policlinico, Mangiagalli, Regina Elena IRCCS, Universita di Milano, Via F Sforza 35, 20122 Milan, Italy
Blood 107:3455-62. 2006..No agranulocytosis, arthropathy, or growth failure was associated with deferasirox administration. Deferasirox is a promising once-daily oral therapy for the treatment of transfusional iron overload...
Oral iron chelatorsMaria Domenica Cappellini
Policlinico, Mangiagalli, Regina Elena Foundation IRCCS, University of Milan, Italy
Annu Rev Med 60:25-38. 2009..The clinical program demonstrated that deferasirox has a safety profile that is clinically manageable with regular monitoring...
Redefining thalassemia as a hypercoagulable stateM Domenica Cappellini
Universita di Milano, Policlinico Foundation IRCCS, Milan, Italy
Ann N Y Acad Sci 1202:231-6. 2010..In this review, the molecular and cellular mechanisms leading to hypercoagulability in thalassemia are highlighted, and the current clinical experience is summarized. Recommendations for thrombosis prophylaxis are also discussed...
Metabolic indicators of oxidative stress correlate with haemichrome attachment to membrane, band 3 aggregation and erythrophagocytosis in beta-thalassaemia intermediaM D Cappellini
Hereditary Anaemia Centre, Ospedale Maggiore IRCCS, Department of Internal Medicine, University of Milano Medical School, Italy
Br J Haematol 104:504-12. 1999....
Overview of iron chelation therapy with desferrioxamine and deferiproneMaria D Cappellini
Universitá di MilanoPoliclinico Foundation IRCCS, Milan, Italy
Hemoglobin 33:S58-69. 2009..The experience with these two drugs helps better delineate the optimal goals of iron chelation therapy and the ideal iron chelator...
Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermediaM D Cappellini
Centre for Congenital Anaemias and Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre and Department of Internal Medicine, IRCCS Maggiore Hospital and University of Milan, Italy
Br J Haematol 111:467-73. 2000....
Insight onto the pathophysiology and clinical complications of thalassemia intermediaMaria D Cappellini
Universita di Milano, Policlinico Foundation IRCCS, Milan, Italy
Hemoglobin 33:S145-59. 2009..However, at present, there are no clear guidelines for an orchestrated optimal treatment plan...
Seven novel point mutations in the uroporphyrinogen decarboxylase (UROD) gene in patients with familial porphyria cutanea tarda (f-PCT)M D Cappellini
Centro Anemie Congenite, Ospedale Maggiore Policlinico IRCCS, Dipartimento di Medicina Interna, University of Milan, Italy
Hum Mutat 17:350. 2001..Three of these mutations have been detected in more than one subject. These results suggest a molecular heterogeneity at the UROD locus in Italian PCT patients although recurrent mutations have been identified...
Butyrate trialsM D Cappellini
Centro Anemie Congenite, Ospedale Maggiore Policlinico IRCCS, Universita di Milano, Italy
Ann N Y Acad Sci 850:110-9. 1998..Serum Epo and sTfR levels were significantly increased during treatment (p < 0.05 vs baseline)...
Porphyrias at a glance: diagnosis and treatmentMaria Domenica Cappellini
Dipartimento di Medicina Interna, Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Via F Sforza 35, 20122, Milan, Italy
Intern Emerg Med 5:S73-80. 2010..The therapeutic approach should be appropriate regarding specific forms of porphyria and treatment should be started promptly...
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemiasMaria Domenica Cappellini
Universita di Milano, Policlinico Foundation IRCCS, Milan, Italy
Haematologica 95:557-66. 2010..gov identifier: NCT00171821)...
Hematologically important mutations: acute intermittent porphyriaMaria Domenica Cappellini
Centro Anemie Congenite, Ospedale Maggiore Policlinico IRCCS, Dipartimento di Medicina Interna, University of Milan, Milan, Italy
Blood Cells Mol Dis 28:5-12. 2002
G6PD Ferrara I has the same two mutations as G6PD A(-) but a distinct biochemical phenotypeM D Cappellini
Istituto di Medicina Interna e Fisiopatologia Medica, Ospedale Maggiore Policlinico, Milano, Italy
Hum Genet 93:139-42. 1994..The 109-bp mutated amplified sequence is not distinguishable from the normal sequence in single strand conformation polymorphism analysis...
Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA studyLuciana Scalone
CIRFF Centre of Pharmacoeconomics, University of Naples Federico II, Naples, Italy CHARTA Foundation member of COPERA, Milan, Italy
Curr Med Res Opin 24:1905-17. 2008..The purpose was to estimate the societal burden attributable to beta-TM in terms of direct and indirect costs, health-related quality-of-life (HRQoL), satisfaction and compliance with ICT in patients undergoing transfusions and ICT...
Novel human pathological mutations. Gene symbol: HMBS. Disease: porphyria, acute intermittentE Di Pierro
Department of Internal Medicine- University of Milan, Centro Anemie Congenite-Maggiore Policlinico, Mangiagalli and Regina Elena Hospital IRCCS. Via F.Sforza, 35 20122 Milan, Italy
Hum Genet 122:417. 2007
Clinical, biochemical and genetic characteristics of Variegate Porphyria in ItalyE Di Pierro
Dipartimento di Medicina Interna, Università degli Studi di Milano Fondazione Ospedale Maggiore Policlinico Mangiagalli e Regina Elena IRCCS Milano, Italy
Cell Mol Biol (Noisy-le-grand) 55:79-88. 2009..Normal urinary excretion of PBG and ALA, predicted absence of neurovisceral symptoms. This paper represents the first compilation of data on genotype-phenotype relation in Italian patients with VP...
Gene symbol: FECH. Disease: Porphyria, erythropoieticValentina Brancaleoni
, F. Sforza, 35, 20122 Milano, Italy
Hum Genet 124:296. 2008
Gene symbol: HMBS. Disease: porphyria, acute intermittentE Di Pierro
Department of Internal Medicine, University of Milan, Centro Anemie Congenite-Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena IRCCS, Milan, Italy
Hum Genet 119:364. 2006
Gene symbol: FECH. Disease: Porphyria, erythropoieticValentina Brancaleoni
, F. Sforza, 35, 20122 Milano, Italy
Hum Genet 124:296. 2008
Lung function in beta-thalassemia patients: a longitudinal studyG Piatti
Istituto di Tisiologia e delle Malattie dell Apparato Respiratorio, Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Fondazione IRCCS, Milano, Italia
Acta Haematol 116:25-9. 2006..An improvement may be observed when good control of the iron balance is reached with optimal chelation therapy...
Novel human pathological mutations. Gene symbol: UROD. Disease: porphyria, cutaneousValentina Brancaleoni
Department of Internal Medicine, University of Milan, Centro Anemie Congenite, Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Fondazione IRCCS, MI, Via F.Sforza, 35, 20122, Milano, Italy
Hum Genet 122:554-5. 2007
Gene symbol: HMBS. Disease: Porphyria, acute intermittentE Di Pierro
Department of Internal Medicine, University of Milan, Centro Anemie Congenite, Maggiore Policlinico Hospital IRCCS, Italy
Hum Genet 116:535. 2005
Co-existence of two functional mutations on the same allele of the human ferrochelatase gene in erythropoietic protoporphyriaE Di Pierro
Department of Internal Medicine, Maggiore Policlinico, Mangiagalli and Regina Elena Foundation IRCCS, University of Milan, Italy
Clin Genet 71:84-8. 2007..By RNA and long polymerase chain reaction analysis, we identified a deletion of 5576 bp (g12490_18067), including exons 3 and 4, in cis with the -250G>C mutation in the promoter...
Gene symbol: HMBS. Disease: porphyria, acute intermittentE Di Pierro
Department of Internal Medicine, University of Milan, Centro Anemie Congenite-Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena IRCCS, Milan, Italy
Hum Genet 119:359. 2006
Gene symbol: HMBS. Disease: porphyria, acute intermittentE Di Pierro
Department of Internal Medicine, University of Milan, Centro Anemie Congenite-Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena IRCCS, Milan, Italy
Hum Genet 119:360. 2006
Gene symbol: FECH. Disease: Porphyria, erythropoietic. Accession #Hg0501E Di Pierro
Department of Internal Medicine, University of Milan, Centro Anemie Congenite-Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena IRCCS, Italy
Hum Genet 118:776. 2006
Gene symbol: CPOXSabrina Ausenda
University of Milan-Maggiore Policlinico Foundation, Internal Medicine, F. Sforza, 35, 20122, Milan, Italy
Hum Genet 121:296. 2007
Novel human pathological mutations. Gene symbol: UROD. Disease: porphyria, cutaneousValentina Brancaleoni
Department of Internal Medicine-University of Milan. Centro Anemie Congenite-Maggiore Policlinico, Mangiagalli and Regina Elena Hospital IRCCS, Milano, F. Sforza, 35, 20122, Milano, Italy
Hum Genet 122:554. 2007
Novel human pathological mutations. Gene symbol: UROD. Disease: porphyria, cutaneousValentina Brancaleoni
University of Milan, IRCCS Foundation Maggiore Hospital, MI, Via F.Sforza, 35, 20122, Milan, Italy
Hum Genet 122:415. 2007
Deferasirox (Exjade) for the treatment of iron overloadM D Cappellini
Fondazione Ospedale Maggiore Policlinico, Istituto di Ricovero e Cura a Carattere Scientifico, Universita di Milano, Milano, Italia
Acta Haematol 122:165-73. 2009..Data continue to accumulate in a wide range of patient groups, including those with non-transfusion-dependent anemias such as hereditary hemochromatosis...
Gene symbol: PPOX. Disease: variegate porphyriaE Patti
Department of Internal Medicine, University of Milan, Milan, Italy
Hum Genet 115:172. 2004
Gene Symbol: FECH. Disease: Porphyria, erythropoieticE Di Pierro
Department of Internal Medicine, University of Milan, Centro Anemie Congenite, Milan, Italy
Hum Genet 114:609. 2004
Gne symbol: PPOX. Disease: variegate porphyriaE Patti
Department of Internal Medicine, University of Milan, Milan, Italy
Hum Genet 115:170. 2004
Gene symbol: HMBS. Disease: porphyria, acute intermittentE Di Pierro
Department of Internal Medicine, University of Milan, Milan, Italy
Hum Genet 115:172. 2004
Human gene mutations. Gene symbol: UROD. Disease: Porphyria, cutanea tardaF Martinez di Montemuros
Dipartimento di Medicina Interna, Centro Anemie Congenite, University of Milan, Ospedale Maggiore Policlinico IRCCS, Via F. Sforza 35, 20122 Milan, Italy
Hum Genet 114:221. 2004
Human gene mutations. Gene symbol: FECH. Disease: Porphyria, erythropoieticE Di Pierro
Department of Internal Medicine, Centro Anemie Congenite, University of Milan, Ospedale Maggiore Policlinico IRCCS, Via F. Sforza 35, 20122 Milan, Italy
Hum Genet 114:221. 2004
Gene symbol: UROD. Disease: Porphyria, cutanea tardaF Martinez di Montemuros
Dipartimento di Medicina Interna, University of Milan--Centro Anemie Congenite, Ospedale Maggiore Policlinico IRCCS, Milan, Italy
Hum Genet 113:368. 2003
Non-transferrin-bound iron in alcohol abusersT M De Feo
Dipartimento di Medicina Interna, , Milano, Italy
Alcohol Clin Exp Res 25:1494-9. 2001..Longitudinal study confirmed the data of the cross-sectional study. CONCLUSIONS: Non-transferrin-bound iron could have a role in initiating or promoting alcohol-induced liver damage...
Molecular characterization of porphyrias in Italy: a diagnostic flow-chartF Martinez di Montemuros
Dipartimento di Medicina Interna, University of Milan, Ospedale Maggiore Policlinico IRCCS, Via F Sforza 35, 20122 Milan, Italy
Cell Mol Biol (Noisy-le-grand) 48:867-76. 2002..Among the 50 molecular defects, 29 seem to be restricted to the Italian population...
Oxidative status and malondialdehyde in beta-thalassaemia patientsGiuliana Cighetti
Department of Medical Chemistry and Biochemistry, Ospedale Maggiore IRCCS, Faculty of Medicine, University of Milan, Via Saldini 50, 20133 Milan, Italy
Eur J Clin Invest 32:55-60. 2002..The aim of this study was to detect and correlate iron overload parameters with the oxidative stress and the antioxidant capability in beta-thalassaemia patients...
Red blood cell antioxidant and iron status in alcoholic and nonalcoholic cirrhosisGemino Fiorelli
Department of Internal Medicine, Ospedale Maggiore Policlinico IRCCS, Padiglione Granelli, University of Milan, Via F Sforza 35, 20122 Milan, Italy
Eur J Clin Invest 32:21-7. 2002..The aim of this study was to assess oxidative damage and red cell indicators of antioxidant defences in alcoholics with mild-to-severe liver cirrhosis, taking into account the iron status...
Gene symbol: HMBS. Disease: Porphyria, acute intermittentE Di Pierro
Department of Internal Medicine, University of Milan, Centro Anemie Congenite, Maggiore Policlinico Hospital IRCCS, Italy
Hum Genet 116:543. 2005
Gene symbol: HMBS. Disease: Porphyria, acute intermittentE Di Pierro
Department of Internal Medicine, University of Milan, Centro Anemie Congenite, Maggiore Policlinico Hospital IRCCS, Italy
Hum Genet 116:537. 2005
Gene symbol: HBMS. Disease: Porphyria, acute intermittentE Di Pierro
Department of Internal Medicine, University of Milan, Centro Anemie Congenite, Milan, Italy
Hum Genet 114:607. 2004
Osteoporosis in beta-thalassaemia major patients: analysis of the genetic backgroundS Perrotta
Dipartimento di Paediatria, II Universita di Napoli, Dipartimento di Medicina Interna, Ospedale Maggiore Policlinico, IRCCS, Milano, Italy
Br J Haematol 111:461-6. 2000..022 and 0.004 respectively), with men more severely affected. Analysis of COLIA1 polymorphism could help to identify those thalassaemic patients at risk of osteoporosis and fractures...
TT virus infection in adult beta-thalassemia major patientsM Sampietro
Dipartimento di Medicina Interna, Universita di Milano, Milan, Italy
Haematologica 86:39-43. 2001..The aims of this study were to assess the prevalence of TTV infection in adult patients with transfusion-dependent thalassemia, and to evaluate the clinical significance of TTV...
Acute intermittent porphyria: heterogeneity of mutations in the hydroxymethylbilane synthase gene in ItalyF Martinez di Montemuros
Centro Anemie Congenite, Ospedale Maggiore Policlinico IRCCS Dipartimento di Medicina Interna, University of Milan, Milan, Italy
Blood Cells Mol Dis 27:961-70. 2001..We can conclude that the mutation screening in the Italian population contributes to improvement of the diagnostic approach of AIP and to establishing possible clustering of mutations in the Mediterranean area...
Gene Symbol: FECH. Disease: Porphyria, erythropoieticE Di Pierro
Department of Internal Medicine, University of Milan, Centro Anemie Congenite, Milan, Italy
Hum Genet 114:608. 2004
Gene symbol: PPOX. Disease: Porphyria, variegateSabrina Ausenda
Department of Internal Medicine, University of Milan, Centro Anemie Congenite, Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Fondazione IRCCS, Milano, F. Sforza, 35, 20122 Milano, Italy
Hum Genet 123:109. 2008
Exercise capacity in patients with beta-thalassaemia intermediaPiergiuseppe Agostoni
Centro Cardiologico Monzino, IRCCS, Istituto di Cardiologia, Universita di Milano, Milan, Italy
Br J Haematol 131:278-81. 2005..Spleen contraction does not significantly influence exercise capacity although exercise-induced haemoconcentration was greater in patients with spleen...
Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis?A Cortelezzi
Servizio Autonomo di Ematologia Diagnostica, Ospedale Maggiore, IRCCS, Milano, Italy
Hematol J 1:153-8. 2000....
Gene symbol: HMBSV Besana
Department of Internal Medicine-University of Milan, Centro Anemie Congenite-Maggiore Policlinico, Mangiagalli and Regina Elena, Foundation IRCCS, Milan, Italy
Hum Genet 121:299. 2007
Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trialCaterina Mariotti
SOSD Genetics of Neurodegenerative and Metabolic Diseases, Fondazione IRCCS, Istituto Neurologico Carlo Besta, Milan, Italy
Mov Disord 27:446-9. 2012..Recently, human recombinant erythropoietin was reported to increase frataxin levels in patients with Friedreich ataxia...
Genetic variability of TMPRSS6 and its association with iron deficiency anaemiaPaola Delbini
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, University of Milan, Italy
Br J Haematol 151:281–4. 2010..Our preliminary results suggest a possible association between specific haplotypes of TMPRSS6 and IRIDA...
Gene symbol: URODValentina Brancaleoni
University of Milan-Maggiore Policlinico Foundation, Internal Medicine, F. Sforza, 35, 20122, Milan, Italy
Hum Genet 121:296-7. 2007
Transfusion-transmitted human parvovirus B19 infection in a thalassemic patientA Zanella
Divisione di Ematologia, Centro Trasfusionale e di Immunologia dei Trapianti, Milan, Italy
Transfusion 35:769-72. 1995..So far, no case of B19 transmission due to single-donor transfusion has been documented...
Novel human pathological mutations. Gene symbol: FECH. Disease: porphyria, erythropoieticV Brancaleoni
Department of Internal Medicine, University of Milan, and Centro Anemie Congenite, Ospedale Maggiore Policlinico, Italy
Hum Genet 121:646. 2007
Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatmentU Ambrosetti
Department of Otolaryngology, University of Milan, Milan, Italy
Pharmacol Res 42:485-7. 2000....
The pituitary-adrenal axis in adult thalassaemic patientsMassimo Scacchi
Chair of Endocrinology, Universita degli Studi di Milano, Division of Endocrinology and Metabolic Diseases, Ospedale San Luca IRCCS, Istituto Auxologico Italiano, Milan, Italy
Eur J Endocrinol 162:43-8. 2010..We previously described in young thalassaemic patients an altered cortisol and ACTH responsiveness suggesting an impaired adrenocortical reserve. Owing to iron overload, a worsening of adrenal function should be expected in adult patients...
Gene symbol: HBBC Refaldi
Department of Internal Medicine-University of Milan, Centro Anemie Congenite-Mggiore Policlinico, Mangiagalli and Regina Elena Foundation IRCCS, Milan, Italy
Hum Genet 121:298. 2007
An erythroid-specific transcript generates the soluble form of NADH-cytochrome b5 reductase in humansA Bulbarelli
Consiglio Nazionale delle Ricerche Center for Cellular and Molecular Pharmacology, Department of Pharmacology, University of Milan, Milan, Italy
Blood 92:310-9. 1998..Our results indicate that the S-transcript is expressed at late stages of erythroid maturation to generate soluble b5R...
Levels of uroporphyrinogen decarboxylase (URO-D) in erythrocytes of Italian porphyria cutanea tarda patientsDario Tavazzi
Centro Anemie Congenite, IRCCS Ospedale Maggiore Policlinico, Padiglione Granelli, Dipartimento di Medicina Intema, , Italy
Cell Mol Biol (Noisy-le-grand) 48:27-32. 2002..8% of patients, suggesting the familial form of PCT (type II). In this group, the outcome of PCT seems to be less influenced by risk factors. Patients with over-normal URO-D activity in RBC deserve further investigation...
Gene symbol: G6PD. Disease: Glucose-6-phosphate dehydrogenase deficiencyPaola Delbini
Department of Internal Medicine, University of Milan, Maggiore Policlinico Foundation IRCCS, Via F. Sforza, 35, 20122 Milan, Italy
Hum Genet 124:312-3. 2008
Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and IranAli Taher
Internal Medicine, American University of Beirut, Beirut, Lebanon
Thromb Haemost 96:488-91. 2006..Due to the increased risk of thromboembolic events, the rationale for splenectomy should perhaps be re-assessed and the role of transfusion therapy for the prophylaxis of thrombosis, among other complications, be evaluated prospectively...
Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH)Giovanna Fabio
Department of Internal Medicine, Università degli Studi di Milano and Fondazione Istituto di Ricovero e Cura a Carattere Scientifico IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milano, Italy
Blood 109:362-4. 2007..To our knowledge, this is the first patient affected by JH treated with combined chelation regimen...
Gene symbol: HAMP. Disease: Haemochromatosis, juvenilePaola Delbini
Department of Internal Medicine, University of Milan, Maggiore Policlinico Foundation IRCCS, Via F. Sforza, 35, 20122 Milan, Italy
Hum Genet 124:313. 2008
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overloadAntonio Piga
Centro Microcitemie, Divisione di Ematologia Pediatrica, Dipartimento di Scienze Pediatriche, Universita di Torino, Italy
Haematologica 91:873-80. 2006..In a phase II study, the tolerability and efficacy of deferasirox were compared with those of DFO in 71 adults with transfusional hemosiderosis...
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia majorCaterina Borgna-Pignatti
Clinica Pediatrica Università di Ferrara, Dipartimento di Medicina Clinica e Sperimentale, Via Fossato di Mortara 17 19, 44100 Ferrara, Italy
Blood 107:3733-7. 2006..In the setting of a natural history study, deferiprone therapy was associated with significantly greater cardiac protection than deferoxamine in patients with thalassemia major...
The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patientsAdriana Ceci
Dipartimento di Farmacologia, Universita di Bari, Fondazione Salvatore Maugeri, Research Institute, Pavia, Italy
Br J Haematol 118:330-6. 2002..These data show that the drug was effective in reducing serum ferritin levels and the incidence of adverse events was not greater than the frequency reported in clinical trials...
Molecular characterization of glucose-6-phosphate dehydrogenase deficiency in the Fars province of IranMehran Karimi
Haematologica 88:346-7. 2003
Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimenRenzo Galanello
Ospedale Regionale Microcitemie, Dipartimento di Scienze, Biomediche e Biotechnologie, Universita di Cagliari, Italy
J Clin Pharmacol 48:428-35. 2008..When this is not feasible, deferasirox should be administered consistently at the same time before meals to limit the sources of variability that affect absorption...
Red blood cell enzyme disorders: an overviewDario Tavazzi
Department of Internal Medicine, University of Milan, Fondazione IRCCS Policlinico, Mangiagalli, Regina Elena, Milan, Italy
Pediatr Ann 37:303-10. 2008
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamineCaterina Borgna-Pignatti
Department of Pediatrics, University of Ferrara
Haematologica 89:1187-93. 2004..The interactions between gender, birth cohort, complications, and ferritin on survival and complications were analyzed...
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disordersEmanuele Angelucci
Hematology Department and BMT Unit, Cancer Center Armando Businco, viale Edward Jenner, 09121 Cagliari, Italy
Haematologica 93:741-52. 2008....
Stroke in thalassemia: a dilemmaAli Taher
Am J Hematol 83:343. 2008
Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 casesDaniele Prati
Dept of Blood Transfusion and Transplantation Immunology, IRCCS Ospedale Maggiore, Milan, Italy
Haematologica 89:1179-86. 2004..We conducted a multicenter study within the Cooleycare Group to describe the clinical and histopathological features of liver disease in currently treated thalassemics...
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective studyJohn Porter
University College London, London, UK
Eur J Haematol 80:168-76. 2008..Dosage was determined by baseline liver iron concentration (LIC)...
A large deletion on chromosome 11 in acute intermittent porphyriaElena Di Pierro
Department of Internal Medicine, Maggiore Policlinico, Mangiagalli and Regina Elena, Foundation IRCCS, University of Milan, Italy
Blood Cells Mol Dis 37:50-4. 2006..Even if the deletions include the entire HMBS and H2AFX genes and 1463 bp of the final portion of DPAGT1 gene, our patients had no other symptoms than AIP...
K-CL co-transport plays an important role in normal and beta thalassemic erythropoiesisLucia De Franceschi
Department of Clinical and Experimental Medicine, University of Verona, Italy
Haematologica 92:1319-26. 2007..We evaluated the possible role of K-Cl co-transport (KCC) in both normal and beta-thalassemic erythropoiesis in vitro...
A 10376 bp deletion of FECH gene responsible for erythropoietic protoporphyriaElena Di Pierro
Department of Internal Medicine, University of Milan Maggiore Policlinico, Mangiagalli and Regina Elena Hospital, Foundation IRCCS, Italy
Blood Cells Mol Dis 40:233-6. 2008....
Changes in erythropoiesis, iron metabolism and oxidative stress after half-marathonLorena Duca
Department of Internal Medicine, University of Milan and IRCCS Ospedale Maggiore Hospital, Mangiagalli e Regina Elena Foundation, Milan, Italy
Intern Emerg Med 1:30-4. 2006..0212) were observed. CONCLUSIONS: The erythropoietic changes observed in marathon runners are the results of several interacting mechanisms that involve either the haemopoietic system per se or erythrocyte haemolysis and oxidative stress...
A point mutation affecting an SP1 binding site in the promoter of the ferrochelatase gene impairs gene transcription and causes erythropoietic protoporphyriaElena Di Pierro
Department of Internal Medicine, Centro Anemie Congenite, Maggiore Policlinico Hospital IRCCS, University of Milan, Milan, Italy
Exp Hematol 33:584-91. 2005..The weaker allele expression has been controversially associated to the presence of different intragenic polymorphisms...
Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathiesGiorgio Derchi
Struttura Complessa di Cardiologia, Ospedali Galliera, Genoa, Italy
Haematologica 90:452-8. 2005..The primary objective of this study was to evaluate the efficacy of sildenafil treatment in the control of PH in patients with hemoglobinopathies...
Beta-thalassemia intermedia: an overviewFuad El Rassi
Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
Pediatr Ann 37:322-8. 2008
Analysis of intelligence quotient in patients with homozygous beta-thalassemiaMehran Karimi
Hematology Research Center, Pediatric Department, Namazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
Saudi Med J 27:982-5. 2006..To compare the intelligence quotient (IQ) of patients with thalassemia major (TM) to that of normal children...
Intrathoracic masses due to extramedullary hematopoiesisRoberto Castelli
Unità Operativa di Medicina d Urgenza e Pronto Soccorso, IRCCS Ospedale Maggiore Policlinico IRCCS Via f Sforza 35, 20122 Milan, Italy
Am J Med Sci 328:299-303. 2004..These observations provide further support to include extramedullary hematopoiesis among the differential diagnosis of tumor-like masses in patients with hematologic diseases...
Hepatocellular carcinoma in the thalassaemia syndromesCaterina Borgna-Pignatti
Dipartimento di Medicina Clinica e Sperimentale Pediatria, University of Ferrara, Ferrara, Italy
Br J Haematol 124:114-7. 2004..Eighty-six percent had been infected by hepatitis C virus. Nineteen of 22 cases were diagnosed after 1993, suggesting that this problem is becoming more frequent with the aging population of thalassaemia patients...
Growth hormone deficiency (GHD) in adult thalassaemic patientsMassimo Scacchi
Chair of Endocrinology, University of Milan, Ospedale San Luca IRCCS, Istituto Auxologico Italiano, Milan, Italy
Clin Endocrinol (Oxf) 67:790-5. 2007..Therefore, we elected to study the growth hormone and insulin-like growth factor-I (GH-IGF-I) axis in a large group of adult thalassaemic subjects...
